Survival analysis of patients with recurrent or metastatic soft tissue sarcoma who were treated by cryoablation: A real-world retrospective study

Aims: This study aimed to evaluate the efficacy and survival factors of cryoablation in the treatment of patients with recurrent or metastatic soft tissue sarcoma (STS).& nbsp;Subjects and Methods: A total of 67 patients with recurrent and metastatic STS who underwent percutaneous cryoablation were included. The neutrophil/lymphocyte ratio (NLR) was calculated based on routine blood test results. The receiver operating characteristic curve (ROC) was used to determine the cut-off NLR value. The efficacy of local ablation for the patients was assessed using the modified Response Evaluation Criteria in Solid Tumors. The primary endpoints were 1-, 2-, and 3-year overall survival (OS) and progression-free survival (PFS).& nbsp;Statistical Analysis Used: Statistical analysis of survival indicators was performed.& nbsp;Results: All 67 patients with STS were evaluated. The prognostic data indicated 1-, 2-, and 3-year OS and PFS rates of 83.58%, 70.15%, and 53.73% and 82.09%, 59.70%, and 46.29%, respectively. ROC analysis demonstrated 3.5 as the cut-off NLR value. A total of 189 cryoablations were performed for 104 lesions in 67 patients with an average ablation rate of 77.92% +/- 24.55%. The objective response rate was 65.38%, and the disease control rate was 86.54%. Univariate analysis exhibited that the preablation NLR, ablation efficacy, postoperative combined treatment regimens, and number of metastasis were associated with the prognosis after cryoablation. The Cox multivariate analysis suggested that these three factors also predicted the superior prognosis of the patients.& nbsp;Conclusions: Cryoablation for patients with recurrent or metastatic STS was associated with potentially superior prognosis in real-world clinical setting. Preablation NLR <= 3.5, <= 3 metastasis, and postoperative combined treatment regimens could be potential biomarkers to predict patient survival.